• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.13% Nasdaq Down1.27%

    Celldex Therapeutics, Inc. (CLDX)

    4.24 Up 0.09(2.17%) 11:19AM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Celldex Therapeutics, Inc.
    Perryville III Building
    Suite 200
    Hampton, NJ 08827
    United States - Map
    Phone: 908-200-7500
    Fax: 908-454-1911
    Website: http://www.celldextherapeutics.com

    Index Membership:N/A
    Full Time Employees:196

    Business Summary 

    Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise Rintega (CDX-110), a therapeutic vaccine in Phase III clinical studies for the treatment of glioblastoma patients that express an epidermal growth factor receptor variant III, as well as in Phase II study for the treatment of recurrent glioblastoma; Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate (ADC) in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma; and Varlilumab (CDX-1127), an immune modulating antibody is in Phase I study for the treatment of multiple solid tumors. It also has various earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, a fully-human monoclonal ADC that targets T cell immunoglobulin and mucin domain 1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding. The company is headquartered in Hampton, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Celldex Therapeutics, Inc.

    Corporate Governance 
    Celldex Therapeutics, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 2. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 1; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Anthony S. Marucci M.B.A., 54
    Founder, Chief Exec. Officer, Pres and Director
    Dr. Tibor Keler Ph.D., 57
    Founder, Chief Scientific Officer and Exec. VP
    Mr. Avery W. Catlin , 68
    Chief Financial Officer, Principal Accounting Officer, Sr. VP, Treasurer and Sec.
    Dr. Thomas Davis M.D. , 52
    Chief Medical Officer and Exec. VP
    Dr. Ronald A. Pepin Ph.D., 60
    Chief Bus. Officer and Sr. VP
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders